ARAY — Accuray Share Price
Last Trade - 00:00- $331.08m
- $387.77m
- $380.33m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 52.99 | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 30th Jun | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 398.8 | 383.41 | 404.9 | 418.79 | 382.93 | 387.49 | 418.68 | 0.16% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +139.29 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.
Directors
- Louis Lavigne NEC (72)
- Joshua Levine (62)
- Shigeyuki Hamamatsu CFO (47)
- Patrick Spine (49)
- Jesse Chew (39)
- Jim Dennison
- Suzanne Winter (57)
- Byron Scott
- Elizabeth Davila IND (76)
- James Hindman (59)
- Beverly Huss (60)
- Anne Le Grand (69)
- Richard Pettingill (72)
- Joseph Whitters (63)
- Last Annual
- June 30th, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- February 22nd, 2001
- Public Since
- February 8th, 2007
- No. of Shareholders
- 193
- No. of Employees
- 932
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 93,260,654
- Address
- 1310 Chesapeake Ter, SUNNYVALE, 94089-1100
- Web
- http://www.accuray.com/
- Phone
- +1 4087164600
- Contact
- Joe Diaz
- Auditors
- Grant Thornton LLP
Latest News for ARAY
Upcoming events for ARAY
Q1 2022 Accuray Inc Earnings Release
Accuray Inc Annual Shareholders Meeting
Similar to ARAY
ABIOMED ORD
NASDAQ Global Select Market
ACUTUS MEDICAL ORD
NASDAQ Global Select Market
AKOYA BIOSCIENCES ORD
NASDAQ Global Select Market
BRUKER ORD
NASDAQ Global Select Market
CERNER ORD
NASDAQ Global Select Market
FAQ
As of Today at 20:44 UTC, shares in Accuray are trading at $3.55. This share price information is delayed by 15 minutes.
Shares in Accuray last closed at $3.55 and the price had moved by +46.69% over the past 365 days. In terms of relative price strength the Accuray share price has outperformed the S&P500 Index by +11.29% over the past year.
The overall consensus recommendation for Accuray is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Accuray does not currently pay a dividend.
Accuray does not currently pay a dividend.
Accuray does not currently pay a dividend.
To buy shares in Accuray you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $3.55, shares in Accuray had a market capitalisation of $331.08m.
Here are the trading details for Accuray:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ARAY
Based on an overall assessment of its quality, value and momentum Accuray is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Accuray is $8.25. That is 132.39% above the last closing price of $3.55.
Analysts covering Accuray currently have a consensus Earnings Per Share (EPS) forecast of $0.03 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Accuray. Over the past six months, its share price has underperformed the S&P500 Index by -44.47%.
As of the last closing price of $3.55, shares in Accuray were trading -22.78% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Accuray PE ratio based on its reported earnings over the past 12 months is 126.79. The shares last closed at $3.55.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Accuray's management team is headed by:
- Louis Lavigne - NEC
- Joshua Levine -
- Shigeyuki Hamamatsu - CFO
- Patrick Spine -
- Jesse Chew -
- Jim Dennison -
- Suzanne Winter -
- Byron Scott -
- Elizabeth Davila - IND
- James Hindman -
- Beverly Huss -
- Anne Le Grand -
- Richard Pettingill -
- Joseph Whitters -
We do not have data on Accuray's shareholders